Anti-cytokine antibodies for rheumatic diseases

Current Opinion in Investigational Drugs

Volumn 10, Issue 11, 2009, Pages 1204-1211

  Atzeni, F ^a   Sarzi Puttini, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti cytokine antibody; Autoimmune disease; MAb; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; AIN 457; AMG 714; BRIAKINUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYTOKINE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MEDI 528; MEPOLIZUMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 11; RILONACEPT; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ADVERSE OUTCOME; ALLERGIC ASTHMA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANKYLOSING SPONDYLITIS; ASTHMA; AUTOIMMUNE DISEASE; BEHCET DISEASE; CELL TYPE; CHONDRITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DEMYELINATING DISEASE; DERMATOMYOSITIS; DRUG ACTIVITY; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GIANT CELL ARTERITIS; GOUT; HEART FAILURE; HEPATITIS; HISTOPLASMOSIS; HUMAN; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; LIVER FAILURE; LUNG ASPERGILLOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MELANOMA; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE POLYP; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; POLYMYOSITIS; PROTEIN FUNCTION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN CANCER; SKIN DISEASE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449413372     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Leonard WJ: Cytokine and cytokine receptor pleiotropy and redundancy. In: Fundamental Immunology. Paul WE (Ed), Lippincott-Raven Publishers, Philadelphia, PA, USA (1999):741-774.
2. Tayal V, Kalra BS: Cytokines and anti-cytokines as therapeutics - An update. Eur J Pharmacol (2008) 579(1-3):1-12.
3. Chin JE, Winterrowd GE, Krzesicki RF, Sanders ME: Role of cytokines in infammatory synovitis. The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fbroblasts. Arthritis Rheum (1990) 33(12):1776-1786.
4. Choy EHS, Panayi GS: Cytokine pathways and joint infammation in rheumatoid arthritis. N Engl J Med (2001) 344(12):907-916.
5. Brennan FM, McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 118(11):3537-3545.
6. Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M: Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum (2002) 46(3):654-662.
7. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF et al: Therapeutic effcacy of multiple intravenous infusions of antitumour necrosis factor ? monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 41(9):1552-1563.
8. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J et al: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet (2004) 363(9410):675-681.
9. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR et al: Infiximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 343(22):1594-1602.
10. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum (2004) 50(5):1400-1411.
11. Furst DE: Certolizumab pegol - What role does this new TNF inhibitor have in the treatment of RAβ Nat Clin Pract Rheumatol (2009) 5(3):134-135.
12. UCB SA: UCB launches CIMplicity program to enhance treatment support for Cimzia (certolizumab pegol) patients and caregivers. Press Release (2008): April 24.
13. UCB SA: UCB's CIMZIA (certolizumab pegol) approved by the US FDA for adult patients suffering from moderate to severe rheumatoid arthritis. Press Release (2009): May 13.
14. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S et al: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 58(4):964-975.
15. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A: A systematic review of the effectiveness of adalimumab, etanercept and infiximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess (2006) 10(42): iii-iv, xi-xiii, 1-229.
16. van Vollenhoven RF: Switching between biological agents. Clin Exp Rheumatol (2004) 22(5 Suppl 35):S115-S121.
17. Kremer JM, Gibofsky A, Greenberg JD: The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol (2008) 20(2):123-130.
18. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG, Marchesoni A, Sarzi-Puttini P: Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev (2009) 8(5):431-437.
19. Atzeni F, Sarzi-Puttini P, DePortu S, Cutolo M, Carrabba M, Straub RH: In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. Clin Exp Rheumatol (2008) 26(1):103-108.
20. Straub RH, Pongratz G, Cutolo M, Wijbrandts CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich J, Lorenz HM et al: Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Rheum (2008) 58(4): 976-984.
21. Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P: Potential target of infiximab in autoimmune and infammatory diseases. Autoimmun Rev (2007) 6(8):529-536.
22. Askling J, Dixon W: The safety of anti-tumor necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol (2008) 20(2):138-144.
23. Desai SB, Furst DE: Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol (2006) 20(4):757-790.
24. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM, Flynn JL, Chan J: Effects of tumor necrosis factor ? on the immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun (2001) 69(3):1847-1855.
25. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P: Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol (2008) 26(1 Suppl 48):S67-S73.
26. Geborek P, Baldström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphoma. Ann Rheum Dis (2005) 64(5):699-703.
27. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S: Tumor necrosis factor ? antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 54(9):2757-2764.
28. Tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009: FDA, Silver Springs, MD, USA (2009). www.fda.gov/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm175843.htm
29. Dinarello CA: Biological basis for interleukin-1 in disease. Blood (1996) 87(6):2095-2147.
30. Nuki G, Bresnihan, B, Bear MB, McCabe D: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 46(11):2838-2846. (Pubitemid 35315874)
31. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIl-1ra), in patients with rheumatoid arthritis. A large, international, multicenter, placebo-controlled trial. Arthritis Rheum (2003) 48(4):927-934.
32. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 46(3):614-624. (Pubitemid 34214243)
33. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N et al: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France. Ann Rheum Dis (2008) 67(3):302-308.
34. Chauffer K, London J, Beaudouin C, Fautrel B: Indications of anakinra. Presse Med (2009) 38(5):799-807.
35. McDermott MF: Rilonacept in the treatment of chronic infammatory disorders. Drugs Today (Barc) (2009) 45(6): 423-430.
36. Senolt L, Vencovský J, Pavelka K, Ospelt C, Gay S: Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev (2009):doi:10.1016/j.autrev.2009.03.010.
37. Naka T, Nishimoto N, Kishimoto T: The paradigm of IL-6: From basic science to medicine. Arthritis Res (2002) 4(Suppl 3):S233-S242.
38. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature (2003) 423(6937):356-361.
39. Nishimoto N: Immunotherapy using IL-6 receptor as the target. Nihon Rinsho Meneki Gakkai Kaishi (2008) 31(5):399-404.
40. Fonseca JE, Santos MJ, Canhão H, Choy E: Interleukin-6 as a key player in systemic infammation and joint destruction. Autoimmun Rev (2009) 8(7):538-542.
41. Roche Holding AG: RoACTEMRA approved in Europe to treat patients suffering from rheumatoid arthritis. Press Release (2009): January 21.
42. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T: Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med (2007) 46(11):771-774.
43. De Benedetti F: Targeting interleukin-6 in pediatric rheumatic diseases. Curr Opin Rheumatol (2009) 21(5):533-537.
44. McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, Sturrock RD, Wilkinson PC, Liew FY: The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med (1996) 2(2):175-182.
45. Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, Zheng XX, Hancock WW, Maslinski W, Li XC, Strom TB, Moll T: Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol (2004) 173(9):5818-5826.
46. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW et al: Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum (2005) 52(9):2686-2692.
47. Genmab A/S: AMG-714 phase II results presented at EULAR conference. Press Release (2006): June 22.
48. Plater-Zyberk C, Joosten LA, Helsen MM, Koenders MI, Baeuerle PA, van den Berg WB: Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor ?-independent mouse model. Ann Rheum Dis (2009) 68(5):721-728.
49. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR: Autoimmune infammation from the Th17 perspective. Autoimmun Rev (2007) 6(3):169-175.
50. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S et al: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune infammation of the brain. Nature (2003) 421(6924):744-748.
51. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pfanz S, Zhang R, Singh KP, Vega F, To W et al: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R?1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 168(11):5699-5708.
52. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB: PHOENIX 1 study investigators: Effcacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet (2008) 371(9625):1665-1674. (Pubitemid 351671883)
53. Marije I, Koenders, Wim B, van den Berg WB: Critical role of IL-17 in experimental arthritis. In: Th 17 cells: Role in infammation and autoimmune disease. Quesniaux V, Ryffel B, Di Padova F (Eds), Birkhäuser, Basel, Switzerland (2009):83-94.
54. Gottlieb AB, Mendelsohn A, Shen YK, Menter A: Randomized, placebo-controlled phase 2 study of ustekinumab, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis. Ann Rheum Dis (2008) 67(Suppl II):99.
55. Andersson AK, Feldmann M, Brennan FM: Neutralizing IL-21 and IL-15 inhibits pro-infammatory cytokine production in rheumatoid arthritis. Scand J Immunol (2008) 68(1):103-111.
56. McInnes IB, Liew FY, Gracie JA: Interleukin-18: A therapeutic target in rheumatoid arthritis? Arthritis Res Ther (2005) 7(1): 38-41.
57. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN: The comparative effcacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol (2008) 33(12):2398-2408.
58. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG: TNF-? antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci (2009) 1173:837-846.
59. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P: Autoimmunity and anti-TNF-? agents. Ann NY Acad Sci (2005) 1051:559-569.
60. Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BA, Nurmohamed MT: High levels of human anti-human antibodies to adalimumab in a patient notresponding to adalimumab treatment. Ann Rheum Dis (2006) 65(9):1249-1250.
61. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B: Development of antiinfiximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 54(3):711-715.